GLMD Stock Overview
A biopharmaceutical company, focuses on the development of Aramchol for the treatment of liver diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Galmed Pharmaceuticals Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.43 |
| 52 Week High | US$23.80 |
| 52 Week Low | US$1.15 |
| Beta | 0.49 |
| 1 Month Change | 14.40% |
| 3 Month Change | -26.29% |
| 1 Year Change | -67.80% |
| 3 Year Change | -98.44% |
| 5 Year Change | -99.85% |
| Change since IPO | -99.95% |
Recent News & Updates
Recent updates
Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?
May 16
Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?
Jan 06Galmed GAAP EPS of -$0.15 beats by $0.09
Aug 04Companies Like Galmed Pharmaceuticals (NASDAQ:GLMD) Could Be Quite Risky
May 03Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?
Jan 15Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?
Oct 02Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Invest In Growth?
May 20What Type Of Shareholders Own The Most Number of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Shares?
Feb 04
We Think Galmed Pharmaceuticals (NASDAQ:GLMD) Can Afford To Drive Business Growth
Dec 06Shareholder Returns
| GLMD | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.9% | 0.1% | 1.7% |
| 1Y | -67.8% | -11.7% | 11.6% |
Return vs Industry: GLMD underperformed the US Biotechs industry which returned -11.7% over the past year.
Return vs Market: GLMD underperformed the US Market which returned 11.6% over the past year.
Price Volatility
| GLMD volatility | |
|---|---|
| GLMD Average Weekly Movement | 18.7% |
| Biotechs Industry Average Movement | 12.1% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: GLMD's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: GLMD's weekly volatility has decreased from 45% to 19% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 5 | Allen Baharaff | galmedpharma.com |
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of Aramchol for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule for the treatment of non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study for HIV-associated lipodystrophy and non-alcoholic fatty liver disease.
Galmed Pharmaceuticals Ltd. Fundamentals Summary
| GLMD fundamental statistics | |
|---|---|
| Market cap | US$3.23m |
| Earnings (TTM) | -US$7.35m |
| Revenue (TTM) | n/a |
Is GLMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GLMD income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$7.35m |
| Earnings | -US$7.35m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.25 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did GLMD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/01 21:38 |
| End of Day Share Price | 2025/05/30 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Galmed Pharmaceuticals Ltd. is covered by 11 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Edward Nash | Canaccord Genuity |
| François Brisebois | Craig-Hallum Capital Group LLC |